Royal Philips announced the expanded commercial availability of LumiGuide 3D Device Guidance, the world's first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States. LumiGuide represents a breakthrough in radiation-free navigation, allowing physicians to visualize and guide devices inside the body using light instead of continuous X-ray. Announced at RSNA 2025, the wider commercial rollout marks the next step in Philips' long-term commitment to improving radiation safety and dose reduction in image-guided therapy.
LumiGuide seamlessly integrates with Azurion, Philips' proven, image-guided therapy platform designed to drive procedural innovation across clinical domains. Using this advanced technology, complex cases such as aortic repair procedures can be performed 37% faster and with up to 56% DAP reduction. Proven Azurion platform: LumiGuide is the latest innovation built on Philips leadership in Image Guided Therapy and the proven Azurion platform - the foundation for procedural innovation across clinical domains.
Seamlessly integrated into Azurion, LumiGuide demonstrates how Philips continues to advance minimally invasive therapies through integration of intelligent systems and devices that combine real-time insight, precision navigation, and procedural efficiency. Built on a platform that treats over 6.4 million patients each year across more than 80 countries, with high-quality, low-dose imaging and enhanced workflow efficiency, LumiGuide extends Philips' commitment to making image-guided therapy safer, faster, and more effective for patients and clinical teams. Together with AI-enabled innovations such as DeviceGuide and VeriSight 3D ICE, Philips is integrating intelligence and imaging to enable the next generation of procedural precision and confidence, all within the connected Azurion environment. LumiGuide builds on Philips' broader portfolio of innovations aimed at reducing or eliminating radiation exposure during image-guided procedures.
Alongside technologies such as Azurion with ClarityIQ, DoseAware, and EchoNavigator, and complementary clinical programs like the RADIQAL trial, LumiGuide underscores Philips' leadership in low- and no-dose interventional solutions, helping to make image-guided therapy safer, more efficient, and more sustainable.
